# MiST (NCT03654833)

> Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03654833
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: University of Leicester
- Conditions: Mesothelioma, Malignant
- Interventions: Rucaparib; Abemaciclib; pembrolizumab & bemcentinib; Atezolizumab & Bevacizumab; Dostarlimab and Niraparib
- Enrollment: 186
- Primary outcome: Disease Control Rate (DCR) at 12 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma.

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4
- Podcasts: 1
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=mist-nct03654833